BioTime, Inc. (NYSEAMERICAN:BTX) Shares Bought by Williams Jones & Associates LLC

Share on StockTwits

Williams Jones & Associates LLC increased its stake in shares of BioTime, Inc. (NYSEAMERICAN:BTX) by 26.5% during the 1st quarter, HoldingsChannel reports. The fund owned 102,111 shares of the biotechnology company’s stock after purchasing an additional 21,371 shares during the quarter. Williams Jones & Associates LLC’s holdings in BioTime were worth $134,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. American International Group Inc. increased its stake in BioTime by 22.1% in the first quarter. American International Group Inc. now owns 71,975 shares of the biotechnology company’s stock valued at $94,000 after purchasing an additional 13,020 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in BioTime by 39.7% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 47,068 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 13,383 shares during the period. Rhumbline Advisers increased its stake in BioTime by 11.4% in the first quarter. Rhumbline Advisers now owns 142,796 shares of the biotechnology company’s stock valued at $187,000 after purchasing an additional 14,579 shares during the period. The Manufacturers Life Insurance Company increased its stake in BioTime by 22.1% in the first quarter. The Manufacturers Life Insurance Company now owns 81,690 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 14,802 shares during the period. Finally, Commonwealth Equity Services LLC increased its stake in BioTime by 20.2% in the first quarter. Commonwealth Equity Services LLC now owns 115,358 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 19,363 shares during the period.

A number of research firms have commented on BTX. Zacks Investment Research lowered shares of BioTime from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 14th. HC Wainwright set a $4.00 price objective on shares of BioTime and gave the company a “buy” rating in a research note on Thursday, May 2nd. Raymond James began coverage on shares of BioTime in a research note on Thursday. They issued a “market perform” rating on the stock. Finally, Maxim Group set a $3.00 price objective on shares of BioTime and gave the company a “buy” rating in a research note on Friday, February 15th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $3.46.

Shares of NYSEAMERICAN:BTX traded down $0.07 during midday trading on Friday, hitting $1.02. The stock had a trading volume of 281 shares, compared to its average volume of 817,952. BioTime, Inc. has a 1 year low of $0.66 and a 1 year high of $2.81.

BioTime (NYSEAMERICAN:BTX) last issued its earnings results on Thursday, May 9th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.36. The firm had revenue of $0.93 million during the quarter, compared to analysts’ expectations of $0.66 million.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/4371578/biotime-inc-nyseamericanbtx-shares-bought-by-williams-jones-associates-llc.html.

BioTime Company Profile

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Featured Story: Understanding Specialty Certificates of Deposit

Want to see what other hedge funds are holding BTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTime, Inc. (NYSEAMERICAN:BTX).

Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Limestone Bancorp  vs. Centerstate Bank  Head to Head Analysis
Limestone Bancorp vs. Centerstate Bank Head to Head Analysis
Beasley Broadcast Group  & Spotify Technology  Head to Head Contrast
Beasley Broadcast Group & Spotify Technology Head to Head Contrast
Contrasting MacroGenics  & Prana Biotechnology
Contrasting MacroGenics & Prana Biotechnology
Contrasting Nexstar Media Group  & FOX
Contrasting Nexstar Media Group & FOX
Contrasting Superior Industries International  and Adomani
Contrasting Superior Industries International and Adomani
Renasant  & Sierra Bancorp  Head-To-Head Review
Renasant & Sierra Bancorp Head-To-Head Review


© 2006-2019 Ticker Report